News highlights and events

View All News

October 2nd, 2024

ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus

Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUAI, (CHINA), October 2, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an...

September 4th, 2023

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR) ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B...

March 30th, 2023

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSᵃⁱ® Integrated Intelligence Technology®, Built Upon the...

Events

Join us at an upcoming event. Contact us to connect or for more information.

Connect with us

Contact Us